Key facts
- It has raised $35.0M; the latest was Later Stage VC ($13.9M) in Mar 2026.
- Notable investors include Samsung Venture Investment, Mirae Asset Capital, Shinhan Venture Investment, Korea Technology Finance, K2 Investment Partners — 17 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 17 names
- ·Watchlist + deal alerts for Medical & Bio Decision
- ·The full record, as it builds
Funding rounds
No funding rounds for Medical & Bio Decision are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Medical & Bio Decision
Developer of a three-dimensional cell culture platform designed to support precision medicine and drug development. The company offers bioengineered cell culture systems and research technologies, enabling pharmaceutical companies and research institutions to study disease mechanisms and improve therapeutic development.
- Sector
- Healthcare
- HQ
- Suwon, South Korea
- Founded
- 2015
- Employees
- 45
- Website
- mbdbiotech.com/
- Ownership
- Privately Held (backing)
Medical & Bio Decision doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Medical & Bio Decision shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Medical & Bio Decision in its N-PORT filings yet. We sweep new filings monthly.